HBK Sorce Advisory’s vTv Therapeutics VTVT Stock Holding History

HBK Sorce Advisory’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,442	Closed	-$38K	–	819
2022 Q4	$38K	Buy	+1,442	New	+$47.7K	﹤0.01%	757

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

HBK Sorce Advisory's VTVT Position: Q1 2023 in Review

HBK Sorce Advisory sold out of vTv Therapeutics (VTVT) in Q1 2023, closing a stake of 1,442 shares — an estimated $38K sold.

HBK Sorce Advisory first reported a position in VTVT in Q4 2022 and held it in 1 quarter. The position peaked at $38K in Q4 2022. 24 funds tracked by Wall St. Rank hold VTVT as of Q1 2023.

HBK Sorce Advisory reported no remaining vTv Therapeutics position as of Q1 2023 after selling out during the quarter.
HBK Sorce Advisory sold 1,442 vTv Therapeutics shares in Q1 2023, an estimated $38K.
HBK Sorce Advisory first reported a position in vTv Therapeutics in Q4 2022 and held it in 1 quarter.
HBK Sorce Advisory's vTv Therapeutics position peaked at $38K in Q4 2022.
24 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2023.

Based on HBK Sorce Advisory's 13F filing for Q1 2023, filed 15 May 2023.